Current approaches for treatment of muscular dystrophies
Muscular dystrophies are the group of hereditary neuromuscular disorders characterized by progressive musclular weakness and degeneration of muscles. The most common of them are Duchenne muscular dystrophy (DMD) and Landouzi-Dejerine facioscapulohumeral muscular dystrophy (FSHD). To date, the pathogenesis of these diseases is well studied that allow to develop various therapeutic approaches for the treatment. Several drugs for the Duchenne muscular dystrophy get through all stages of clinical trials approved by FDA (food drug administration) and are utilized for treatment. Pathogenesis of FSHD differs substantially from DMD, and therapeutic approaches are only under development. Molecular and cellular technologies as well as the understanding of the disease pathogenesis allow to hope for a quick success in this area.